Form 4: Theravance Biopharma SVP Sells Shares for Tax

Aine Miller, SVP at Theravance Biopharma, disposed of 6,989 ordinary shares to cover tax obligations from restricted stock unit vesting.

Summary

• Aine Miller, SVP, DEV & HEAD OF IRE OFFICE at Theravance Biopharma, Inc., disposed of 6,989 ordinary shares.
• The transaction occurred on August 20, 2025, at a price of $13.39 per share.
• These shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following this transaction, Aine Miller directly beneficially owns 208,001 ordinary shares.
• The transaction was not an open market sale but an internal withholding by the issuer.

Sentiment

Score: 5

Explanation: A routine Form 4 filing indicating a non-discretionary share disposition for tax purposes, which has a neutral impact on company fundamentals or outlook.

Positives

• No open market sale by the executive, indicating the disposition was for a specific, non-discretionary purpose (tax obligations).

Negatives

• A reduction in the executive's direct shareholding by 6,989 shares.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details a routine executive share disposition for tax purposes, a common occurrence in public companies when restricted stock units vest. It does not provide broader industry insights or competitive analysis.

Comparison to Industry Standards

• The share withholding for tax obligations upon RSU vesting is a standard practice across publicly traded companies, including peers in the biopharmaceutical sector.
• This transaction aligns with typical executive compensation and tax management procedures, similar to those observed at companies like Amgen or Gilead Sciences when executive equity awards vest.

Related Party Transactions

• The share withholding transaction was conducted with the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, which is a common form of related party transaction for executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related transaction, not a discretionary sale. It slightly reduces the executive's direct ownership.
• Employees: No direct impact on general employees.
• Management: Aine Miller's beneficial ownership is adjusted, but the transaction is a standard part of executive compensation.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Share Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation, Aine Miller